Octreotide - Pharm-SintezAlternative Names: Octreotide-depo; Oktreotid-depo
Latest Information Update: 20 Nov 2015
At a glance
- Originator Pharm-Sintez
- Class Antineoplastics; Antisecretories; Cyclic peptides; Indoles; Somatostatins
- Mechanism of Action Growth hormone releasing factor antagonists; Somatostatin receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Acromegaly; Gastrointestinal cancer; Haemorrhage; Pancreatic cancer; Pancreatitis; Prostate cancer
Most Recent Events
- 15 Mar 2016 Biomarkers information updated